Olumiant-话题@MedSci

#Olumiant#

5篇内容 | 585人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1981832, encodeId=e3f3198183283, content=<a href='/topic/show?id=bda71331e52' target=_blank style='color:#2F92EE;'>#Olumiant#</a>, objectTitle=JAK 抑制剂 Olumiant 在 RA 中的新长期阳性数据, objectType=article, longId=220347, objectId=48aa22034ed7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48aa22034ed7, replyNumber=0, likeNumber=34, createdTime=2022-07-30, rootId=0, userName=tongyongming, userId=76d3356, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48aa22034ed7, moduleTitle=JAK 抑制剂 Olumiant 在 RA 中的新长期阳性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48aa22034ed7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1981833, encodeId=9b3819818333c, content=<a href='/topic/show?id=bda71331e52' target=_blank style='color:#2F92EE;'>#Olumiant#</a>, objectTitle=礼来（Lilly）的Olumiant在狼疮、特应性皮炎适应症中遭遇挫折, objectType=article, longId=295103, objectId=2e0c295103eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e0c295103eb, replyNumber=0, likeNumber=38, createdTime=2022-09-17, rootId=0, userName=tongyongming, userId=76d3356, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e0c295103eb, moduleTitle=礼来（Lilly）的Olumiant在狼疮、特应性皮炎适应症中遭遇挫折, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e0c295103eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1981831, encodeId=473a1981831c4, content=<a href='/topic/show?id=bda71331e52' target=_blank style='color:#2F92EE;'>#Olumiant#</a>, objectTitle=JAK抑制剂Olumiant和抗血管生成素-2单抗LY3127804将用于新冠病毒COVID-19患者临床试验, objectType=article, longId=192249, objectId=f473192249cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f473192249cd, replyNumber=0, likeNumber=35, createdTime=2020-04-26, rootId=0, userName=tongyongming, userId=76d3356, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f473192249cd, moduleTitle=JAK抑制剂Olumiant和抗血管生成素-2单抗LY3127804将用于新冠病毒COVID-19患者临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f473192249cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1981830, encodeId=bcd81981830aa, content=<a href='/topic/show?id=bda71331e52' target=_blank style='color:#2F92EE;'>#Olumiant#</a>, objectTitle=JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点, objectType=article, longId=178209, objectId=6ad01e8209da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ad01e8209da, replyNumber=0, likeNumber=37, createdTime=2020-05-21, rootId=0, userName=tongyongming, userId=76d3356, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ad01e8209da, moduleTitle=JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ad01e8209da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1981829, encodeId=7c09198182909, content=<a href='/topic/show?id=bda71331e52' target=_blank style='color:#2F92EE;'>#Olumiant#</a>, objectTitle=礼来JAK抑制剂Olumiant治疗系统性红斑狼疮的2期临床试验获得成功, objectType=article, longId=145138, objectId=96a9145138b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96a9145138b2, replyNumber=0, likeNumber=42, createdTime=2018-11-01, rootId=0, userName=tongyongming, userId=76d3356, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96a9145138b2, moduleTitle=礼来JAK抑制剂Olumiant治疗系统性红斑狼疮的2期临床试验获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96a9145138b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Olumiant

2020-05-29

tongyongming (审核中...)

前往app查看评论内容

#Olumiant#

JAK 抑制剂 Olumiant 在 RA 中的新长期阳性数据

2022-07-30

tongyongming (审核中...)

前往app查看评论内容

#Olumiant#

礼来（Lilly）的Olumiant在狼疮、特应性皮炎适应症中遭遇挫折

2022-09-17

tongyongming (审核中...)

前往app查看评论内容

#Olumiant#

JAK抑制剂Olumiant和抗血管生成素-2单抗LY3127804将用于新冠病毒COVID-19患者临床试验

2020-04-26

tongyongming (审核中...)

前往app查看评论内容

#Olumiant#

JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点

2020-05-21

tongyongming (审核中...)

前往app查看评论内容

#Olumiant#

礼来JAK抑制剂Olumiant治疗系统性红斑狼疮的2期临床试验获得成功

2018-11-01

科室
- - 订阅+
  - 更多科室
工具
服务